Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
4
×
ipo
life sciences
national blog main
national top stories
4
×
san francisco blog main
san francisco top stories
boston top stories
clinical trials
sanofi
venture capital
biogen
boulder/denver blog main
boulder/denver top stories
cancer drugs
deals
deerfield management
detroit blog main
detroit top stories
europe blog main
europe top stories
fda
gilead sciences
indiana blog main
indiana top stories
melinta therapeutics
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
revolution medicines
san diego blog main
san diego top stories
san francisco
seattle blog main
seattle top stories
What
ipo
4
×
medicines
4
×
bio
cancer
covid
proteins
research
revolution
roundup
acquisitions
activity
announced
approvals
biogen
cancer’s
ceo
clamped
collabs
daniel
deal
delays
despite
developing
disease
drug
economic
family
fast
fda
frontiers
gilead
gilead’s
hardest
help
hit
hottest
hunters
including
introduce
isn’t
Language
unset
Current search:
medicines
×
cancer
×
" national top stories "
×
ipo
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers